The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept…
COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered…